Patents Assigned to ModernaTX, Inc.
-
Publication number: 20240102066Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.Type: ApplicationFiled: August 11, 2023Publication date: March 28, 2024Applicant: ModernaTX, Inc.Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
-
Patent number: 11939601Abstract: This disclosure relates to mRNA therapy for the treatment of hyperphenylalaninemias such as phenylketonuria (PKU). mRNAs for use in the invention, when administered in vivo, encode human phenylalanine hydroxylase (PAH), functional fragments thereof (e.g., those comprising the catalytic domain or the catalytic domain and the tetramerization domains), and fusion proteins comprising PAH. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PAH expression and/or activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of phenylalanine associated with deficient PAH activity in subjects.Type: GrantFiled: November 21, 2018Date of Patent: March 26, 2024Assignee: ModernaTX, Inc.Inventors: Raj Rajendran, Patrick Finn, Paolo G. V. Martini, Ding An, Athanasios Dousis, Kanchana Ravichandran
-
Patent number: 11918644Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.Type: GrantFiled: April 30, 2021Date of Patent: March 5, 2024Assignee: ModernaTX, Inc.Inventor: Giuseppe Ciaramella
-
Patent number: 11911453Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.Type: GrantFiled: January 28, 2019Date of Patent: February 27, 2024Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
-
Patent number: 11912982Abstract: Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides having hydrophobic portions (e.g., polyadenylated nucleic acids, such as mRNA) based upon the hydrophobic character of the molecules (e.g., polyA tail length). In some embodiments, the disclosure describes liquid chromatographic methods for separating a nucleic acid having a hydrophobic portion (e.g., a polyadenylated nucleic acid, such as an mRNA) from a complex mixture by a mobile phase system that comprises an ion pairing agent selected from Tris, inorganic cations (including e.g., Na, Li, K, ammonium, etc.), biological buffers (e.g., MOPS, HEPES, PIPES, etc.), and other charged or hydrophilic moieties, and lacks conventional ion pairing agents (e.g., Triethylammonium acetate, TEAA). Accordingly, in some embodiments methods described by the disclosure are useful for assessing the quality of pharmaceutical preparations comprising nucleic acids.Type: GrantFiled: August 17, 2018Date of Patent: February 27, 2024Assignee: ModernaTX, Inc.Inventors: William Issa, Meredith Packer
-
Patent number: 11911474Abstract: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.Type: GrantFiled: January 5, 2021Date of Patent: February 27, 2024Assignee: ModernaTX, Inc.Inventors: Antonin De Fougerolles, Sayda M. Elbashir
-
Patent number: 11905525Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering nucleic acids in vivo. These compositions have reduced immune activation resulting in accelerated blood clearance and/or anti-drug antibodies and they have an improved toxicity profile and therapeutic index in vivo.Type: GrantFiled: April 5, 2018Date of Patent: February 20, 2024Assignee: ModernaTX, Inc.Inventors: Luis Brito, Gilles Besin
-
Publication number: 20240025935Abstract: The present invention relates to compositions and methods for the purification of ribonucleic acids including a polyA tail. The compositions and methods include a polystyrene divinylbenzene particle, a linker, and a poly-deoxythymidine oligonucleotide.Type: ApplicationFiled: November 18, 2021Publication date: January 25, 2024Applicant: ModernaTX, Inc.Inventors: Bill KELLEHER, Michael SHAMASHKIN
-
Publication number: 20240016827Abstract: Provided herein are compositions and methods of reducing adduct formation.Type: ApplicationFiled: June 2, 2023Publication date: January 18, 2024Applicant: ModernaTX, Inc.Inventors: Meredith Packer, Dipendra Gyawali, Serenus Hua, Gabor Butora, Gregory John Mercer
-
Patent number: 11873327Abstract: The present disclosure relates to polynucleotides encoding tethered interleukin-12 (IL-12) polypeptides comprising an IL-12 polypeptide and a membrane domain. The present disclosure also relates to vectors comprising the polynucleotides; host cells comprising the polynucleotides or vectors, polypeptides encoded by the polynucleotides; compositions comprising the polynucleotides, vectors, host cells, or polypeptides and a delivery agent; and uses thereof, including treatment of cancer.Type: GrantFiled: July 28, 2022Date of Patent: January 16, 2024Assignee: ModernaTX, Inc.Inventors: Ankita Mishra, Joshua Frederick, Sushma Gurumurthy
-
Patent number: 11872278Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: GrantFiled: June 10, 2020Date of Patent: January 16, 2024Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu
-
Patent number: 11866754Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.Type: GrantFiled: October 17, 2016Date of Patent: January 9, 2024Assignee: ModernaTX, Inc.Inventors: Gabor Butora, Matthew Stanton, Edward John Miracco
-
Patent number: 11866475Abstract: The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.Type: GrantFiled: June 6, 2017Date of Patent: January 9, 2024Assignee: ModernaTX, Inc.Inventors: Leif Karlsson Parinder, Regina Desirée Fritsche Danielson, Kenny Mikael Hansson, Li Ming Gan, Jonathan Clarke, Ann-Charlotte Eva Egnell, Kenneth Randall Chien
-
Patent number: 11866696Abstract: Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides of various lengths, sequences, and/or base compositions in a highly tunable manner. In some embodiments, the disclosure describes liquid chromatographic methods for separating a nucleic acid (e.g., a polyadenylated nucleic acid, such as an mRNA) from a complex mixture by using multiple ion pairing agents in the same mobile phase system. Accordingly, in some embodiments methods described by the disclosure are useful for assessing the quality of pharmaceutical preparations comprising nucleic acids.Type: GrantFiled: August 17, 2018Date of Patent: January 9, 2024Assignee: ModernaTX, Inc.Inventors: William Issa, Meredith Packer
-
Publication number: 20240000917Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.Type: ApplicationFiled: May 24, 2023Publication date: January 4, 2024Applicant: ModernaTX, Inc.Inventor: Giuseppe Ciaramella
-
Patent number: 11859215Abstract: This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.Type: GrantFiled: November 21, 2018Date of Patent: January 2, 2024Assignee: ModernaTX, Inc.Inventors: Zhijian Zhuo, Andrea Lea Frassetto, Paolo G. V. Martini, Vladimir Presnyak, Patrick Finn
-
Patent number: 11851694Abstract: The present disclosure provides methods and compositions for high fidelity in vitro transcription reactions.Type: GrantFiled: February 19, 2020Date of Patent: December 26, 2023Assignee: ModernaTX, Inc.Inventors: David Mauger, Vladimir Presnyak, Amy E. Rabideau, Iain Mcfadyen
-
Patent number: 11845772Abstract: Disclosed herein are methods for purifying RNA comprising poly A. Also disclosed herein are compositions such as surfaces and oligonucleotides for purifying RNA comprising polyA. Other embodiments are also disclosed. Commercially-available resins having polythymidine oligonucleotide ligands typically contain less than 30 thymidine (2?deoxy) residues and some commercial resin suppliers utilize a distribution of dT chain lengths, not of a discreet length.Type: GrantFiled: June 30, 2022Date of Patent: December 19, 2023Assignee: ModernaTX, Inc.Inventors: William Joseph Issa, John Grant Aunins, Stephane Bancel
-
Publication number: 20230390379Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: May 10, 2023Publication date: December 7, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Publication number: 20230381301Abstract: Provided herein, in some embodiments, are vaccines (and vaccination methods) that include a ribonucleic acid (RNA) polynucleotide encoding a human metapneumovirus (hMPV) F protein and a RNA polynucleotide encoding a human parainfluenza virus 3 (hPIV3) F protein.Type: ApplicationFiled: March 24, 2023Publication date: November 30, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu